业界动态国内医卫资讯

FDA批准度伐利尤单抗联合恩诺单抗维多汀用于肌层浸润性膀胱癌

Medscape News · 2026-11-14 05:23

摘要

随着该批准,对于不适合顺铂的肌层浸润性膀胱癌患者,围手术期帕博利珠单抗联合恩诺单抗维多汀有了一个竞争对手。Medscape Medical News

English
FDA Approves Durvalumab With Enfortumab Vedotin for MIBC

With the approval, there's a rival to perioperative pembrolizumab with enfortumab vedotin for patients with cisplatin-ineligible muscle-invasive bladder cancer. Medscape Medical News

内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界